TG Therapeutics, Inc.TGTXNASDAQ
LOADING
|||
TGTX Revenue Growth (YoY Quarterly)•+92.79%
SAPRO
Growth Metrics
| Metric | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 |
|---|---|---|---|---|---|
| Revenue Growth | -49.41% | +146.04% | +90.40% | +92.13% | +92.79% |
| Gross Profit Growth | -54.08% | +157.56% | +81.73% | +87.55% | +79.18% |
| EBITDA Growth | -87.12% | +0.00% | +0.00% | +255.61% | +115.59% |
| Operating Income Growth | -89.17% | +0.00% | +0.00% | +295.22% | +136.17% |
| Net Income Growth | -96.59% | +0.00% | +0.00% | +309.75% | +9974.61% |
| EPS Growth | -96.25% | +0.00% | +0.00% | +300.00% | +8866.67% |
| EPS Diluted Growth | -97.26% | +0.00% | +0.00% | +293.52% | +12050.00% |
| Weighted Average Shares Growth | +1.56% | +1.50% | +0.32% | +1.39% | +0.22% |
| Weighted Average Shares Diluted Growth | +3.11% | +11.99% | +11.33% | +1.97% | +0.18% |
| Dividends per Share Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Cash Flow Growth | -114.58% | +0.00% | +0.00% | +34.32% | +0.00% |
| Free Cash Flow Growth | -114.61% | +0.00% | +0.00% | +33.56% | +0.00% |
| Receivables Growth | +194.32% | +152.84% | +192.57% | +176.91% | +129.32% |
| Inventory Growth | +152.34% | +177.37% | +102.99% | +91.03% | +73.56% |
| Asset Growth | +77.01% | +75.28% | +75.90% | +75.12% | +74.91% |
| Book Value per Share Growth | +14.83% | +36.49% | +47.73% | +53.54% | +215.32% |
| Debt Growth | +130.93% | +129.00% | +127.20% | +125.45% | -0.04% |
| R&D Expense Growth | +36.50% | +36.82% | +41.68% | +81.03% | +102.99% |
| SG&A Expenses Growth | +28.07% | +25.44% | +45.89% | +43.56% | +50.86% |
1 / 4